Kohta Saito, MD, MPH
Basic profileKohta Saito is an Infectious Disease physician affiliated with Weill Cornell Medicine. OpenAlex indexes 46 publications with 665 citations (h-index 15).
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
100%Antimycobacterial34.1%Ethambutol Hcl100%Part D<11 patientsMacrolide Antimicrobial31.3%Azithromycin100%Part D≥12 patients+ 3 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
2 NIH research awards on record, funded 2019–2025 per NIH RePORTER. The latest:
- Interrogating complex mycobacterial population structures using single-cell RNA sequencing
Weill Medical Coll of Cornell Univ
FY2025$211,875R21AI176355 - Interrogating complex mycobacterial population structures using single-cell RNA sequencing
Weill Medical Coll of Cornell Univ
FY2024$254,250R21AI176355 - Identifying the Molecular Target of Two Novel Compounds Active Against Non-replicating Mycobacterium tuberculosis and Delineating the Role of the Putative Target, InhA, in Non-replicating States
Weill Medical Coll of Cornell Univ
FY2023$172,006K08AI139360
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Desiccation promotes DNA damage and rifampin resistance in Mycobacterium tuberculosis
Nature Microbiology
2026 - Desiccation-induced DNA damage facilitates drug resistance in Mycobacterium tuberculosis
bioRxiv (Cold Spring Harbor Laboratory)
2025 - High variance in quantification of Mycobacterium tuberculosis at low bacterial loads and with differentially detectable mycobacteria
Antimicrobial Agents and Chemotherapy
2024 - Clinically encountered growth phenotypes of tuberculosis-causing bacilli and their in vitro study: A review
Frontiers in Cellular and Infection Microbiology
2022
Similar KOLs
Other experts from the same institution or the same specialty.
Jedd Wolchok, MD
Weill Cornell Medicine
Richard Devereux, MD
Weill Cornell Medicine
Ronald Crystal, MD
Weill Cornell Medicine
Robert Harrington, MD
Weill Cornell Medicine
Thomas Walsh, MD
Cornell University
Douglas Richman, MD
University of California San Diego
Henry Masur, MD
National Institutes of Health
Vance Fowler, MD
Duke University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”